Resolve Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Resolve Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Resolve Therapeutics: 4 sponsored US clinical trials, 1 recruiting.
Resolve Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Sjögren Syndrome, with 1 trials.
Upper-quartile sponsor footprint
Resolve Therapeutics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525
Phase 2 Study of RSLV-132 in Subjects With Long COVID
NCT04944121
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT02660944
Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
NCT02194400
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Resolve Therapeutics pipeline
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Primary Sjögren Syndrome (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Resolve Therapeutics: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Resolve Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Resolve Therapeutics page
4 registered trials is a research-attention snapshot, not an endorsement of Resolve Therapeutics or any single study.
- 1 of Resolve Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Sjögren Syndrome is the condition Resolve Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Sjögren Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Resolve Therapeutics pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.